Investigate potential differences in adrenergic and muscarinic receptor autoantibody levels in plasma and cerebrospinal fluid (CSF) samples between ME/CFS patients and healthy controls, examine why these autoantibodies start to show up in the disease process and how we might positively impact this process with various drug targets and immune regulatory treatments. Being able to explain these underlying mechanisms may provide the validation needed for specific ongoing treatments.
Completed validation study on the presence of autoantibodies in plasma in two Swedish ME/CFS cohorts, and paper published.
Observed a significant up-regulation of autoantibodies in up to 70% of patients. Significantly increased autoantibodies against adrenergic and muscarinic receptors have been found in the plasma of ME/CFS patients.
No autoantibodies could be found in CFS, which is positive news as that would make the removal of autoantibodies very difficult.
Preliminary studies using immunoadsorption and / or plasmapheresis to remove autoantibodies show positive effects in at least a sub-population of ME/CFS patients.
Collection of data is ongoing and should be ready for evaluation in fall 2022.
The development of autoimmune antibodies is a consistent finding across HSE, ME/CFS, Long COVID and provide a window into the neurocognitive disturbances, peripheral symptoms, POTS, pain, and other targets of these autoantibodies.
Previously, autoantibodies have been observed to have increased binding to adrenergic and muscarinic receptors in ME/CFS patients. It is hypothesized
that these autoantibodies may be part of the pathogenesis of ME/CFS and patient symptom.
Plasma, CSF and health-related questionnaires were collected from two Swedish ME / CFS cohorts, plasma and CSF from one of the cohorts (n=24), only plasma from the second cohort (n=24) together with plasma samples (n=24) and CSF (n=6) from healthy controls.
All samples were analyzed for IgG autoantibodies directed against adrenergic and muscarinic receptors ELISA technique. The questionnaires were used as measures of disease severity.
This study has been published in Brain, Behavior and Immunity – Health
Donate your appreciated stock directly to OMFCA and you can receive an immediate income-tax deduction for the fair market value of the securities on the date of transfer (even if you originally paid much less for them).
OMFCA sells your securities and uses the proceeds to support our mission. You also do not pay capital gains tax on the transfer when the stock is sold. Giving appreciated stock can be more beneficial than giving cash. The “cost” of your gift is often less than the deduction you gain by making it. In advance, thank you for making this generous gift.
Gifting of Stock Instructions
Brokerage/Investment Firm: TD Waterhouse
Name on the Account: Open Medicine Foundation Canada
Account Number: 20LRHLA
OMFCA Canadian Revenue Agency (CRA) charity registration #: 74926 5518 RR0001
OMF Canada Registered Address:
Open Medicine Foundation Canada
2987 Baynes Road, Victoria, BC V8N-1Y4
Phone Number: 416-848-0055
Please speak to your personal tax advisor and then call OMFCA at 650-242-8669 to notify us of your donation or with any questions.